NYSE · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · MID CAP
Usana Health Sciences, Inc. USNA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$925.3M
▲ 8.3% vs FY2024
EPS · FY25
$0.58
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
2.0%
Net margin · FY25
1.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 925.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
1 cents of every revenue dollar became profit this year.
Per share
USD 0.58
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
2.0%
Return on equity, FY2025
ROE
Operating margin4.0%
Net margin1.2%
Return on assets1.4%
Each USD of equity produced 2 cents of profit this year.
Returned to shareholders
USD 27.5M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 27.5M
Share of profit255.6%
Consecutive raises—
USD 27.5M in buybacks — 256% of the year's profit, so the payout drew on cash built up earlier.
Growth
−4.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.5%
−4.0%
+0.1%
+3.9%
Net income
−46.3%
−38.7%
−19.5%
−9.2%
EPS, diluted
−45.5%
−37.0%
−16.7%
Returned to shareholders
+2.7%
−13.6%
−7.7%
+12.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years−13.1%
Change, 10 years−26.8%
The share count shrank 13% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 742.9M
total assets, end of FY2025
Total assetsUSD 742.9M
EquityUSD 533.1M
CashUSD 158.4M
Current ratio2.24×
Equity funds 72% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.9
0.9
0.9
1.0
1.2
1.1
1.1
1.2
1.0
1.0
0.9
0.8
0.7
0.6
0.6
0.5
0.4
Operating income $B
0.0
0.1
0.1
0.1
0.2
0.2
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
EBITDA $B
0.1
0.1
0.1
0.1
0.2
0.2
0.2
0.2
0.1
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
Income tax $B
0.0
0.0
0.0
0.0
0.1
0.1
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
EPS, diluted $
0.58
2.19
3.30
3.59
5.73
5.86
4.41
5.12
2.53
3.99
3.59
2.80
5.56
4.45
3.26
2.86
2.17
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
2.0
8.2
13.7
16.7
27.8
31.4
27.1
33.5
18.2
33.0
37.1
31.2
35.4
37.0
31.6
41.3
45.1
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed